Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer.

Autor:	Bordry N; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Addeo A; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Jaksic C; CRC& Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and Geneva University Hospital, Geneva, Switzerland., Dutoit V; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Roux-Lombard P; Immunology and Allergology Laboratory, Geneva University Hospital, University of Geneva, 1205 Geneva, Switzerland., Shah DP; Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA., Shah PK; Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA., Gayet-Ageron A; CRC& Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and Geneva University Hospital, Geneva, Switzerland., Friedlaender A; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland.; Oncology Department, University Hospital of Geneva, Switzerland, Clinique Générale Beaulieu, Geneva, Switzerland., Bugeia S; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Gutknecht G; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Battagin A; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Di Marco M; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Simand PF; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Labidi-Galy I; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Fertani S; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Sandoval J; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Dietrich PY; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Mach N; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland.
Jazyk:	angličtina
Zdroj:	IScience [iScience] 2021 Dec 24; Vol. 25 (1), pp. 103699. Date of Electronic Publication: 2021 Dec 24 (Print Publication: 2022).
DOI:	10.1016/j.isci.2021.103699
Abstrakt:	Little is known on the long-lasting humoral response and the T cell activation induced by SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the SARS-CoV-2 mRNA vaccines through measuring the seroconversion rate at pre-specified time points and the effect on the T cell immunity in patients with cancers. The study included 131 adult patients with solid or hematological cancer, who received SARS-CoV-2 mRNA vaccines. 96.2% of them exhibited adequate antibody response to the SARS-CoV-2 mRNA vaccines 2 months after the booster dose. SARS-CoV-2 mRNA vaccines could induce T cell activation; however, this is more likely in patients who have a positive seroconversion (94%) compared with the patients who did not (50%). Further research into the clinical relevance of low antibodies titers and lack of T cell activity is required to set up an effective vaccination strategy within this group of patients. Competing Interests: AA reported receiving personal fees for attending advisory from Bristol-MyersSquibb, 10.13039/100011338AstraZeneca, 10.13039/100004337Roche, 10.13039/100004319Pfizer, 10.13039/100009947Merck Sharp and Dohme, 10.13039/100004324Astella, 10.13039/100004312Eli Lilly, and 10.13039/100001003Boehringer-Ingelheim and receiving fees for speaking bureau for Eli Lilly, AstraZeneca, MSD for work performed outside of the current study. NM is a founder and minority shareholder of MaxiVAX SA, a private biotech company based in Geneva, Switzerland, working on personalized cancer immunotherapy and infectious disease vaccines, with no impact on the current manuscript. PS reported receiving grant from the Biomedical Advanced Research and Development Authority outside of this work. All other co-authors reported no competing interests. (© 2022 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu